费洛登德林可以缓解肠道炎症,并通过调节COL1A1,VCAM1和IL-17a来保护粘膜屏障
Wen Shi1, Huanhuan Sun1, Qingqing Yao1
1Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
费洛登德林 (PHE) 通过减少炎症和修复肠道屏障,有效治疗炎症性肠病 (IBD). 这种天然化合物显示出作为IBD治疗剂的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 菲洛登德林 (PHE) 具有抗炎和抗氧化特性.
- 在炎症性肠病 (IBD) 中PHE的治疗潜力需要进一步研究.
- IBD的发病过程涉及复杂的炎症和免疫反应.
研究的目的:
- 研究PHE在治疗IBD中的疗效和潜在机制.
- 用生物信息学和虚拟查来确定IBD的治疗点.
- 评估PHE对肠道炎症的体内和体外模型的影响.
主要方法:
- 使用硫酸德克斯 (DSS) 建立了一种小鼠结肠炎模型.
- 向小鼠和Caco-2细胞施用PHE,以评估其对炎症和细胞活力的影响.
- 利用生物信息学,虚拟查,组织学分析,CCK-8检测,流细胞计和西斑分析分子机制.
主要成果:
- 确定了COL1A1和VCAM1作为IBD的关键治疗点.
- 在小鼠中,PHE治疗缓解了结肠炎症状,减少了炎症并改善了组织完整性.
- 在体外研究表明,PHE保护Caco-2细胞免受通过AMPK/mTOR通路的脂多糖 (LPS) 诱导的损伤.
结论:
- 在IBD模型中,PHE改善了肠道炎症和屏障功能障碍.
- PHE的治疗效果很可能通过调节COL1A1,VCAM1,IL-17A和AMPK/mTOR途径来调节.
- PHE证明了作为IBD治疗的新型天然治疗剂的潜力.
更多相关视频
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Mucosal Barrier of the Stomach
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Renewal of Intestinal Stem Cells
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Physiology of Enteric Nervous System and Gut Health
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
